Gail McIntyre, Ph.D., DABT
Chief Executive Officer & Board Director
Gail McIntyre, Ph.D., is a seasoned biopharma executive with more than 25 years of experience. Dr. McIntyre has been Aravive’s Chief Executive Officer since April 2020. Previously she was Chief Scientific Officer since February 2019 and has been with the company since August 2016 as head of R&D. Having brought multiple drugs to market, Dr. McIntyre’s drug development expertise spans multiple disciplines and therapeutic areas as well as strategic business development, licensing and M&A. Previously, Dr. McIntyre served as a principal at IntelliDev Consulting, LLC providing consulting services to several biotechnology companies for three years including heading development of a cancer company from Jan 2014 to Jan 2016. Prior to that, Dr. McIntyre held the position of Senior Vice President of research at Furiex Pharmaceuticals, Inc. and previously served as Head of Pharmaceutical Product Development (PPD) LLC’s compound partnering business. At both Furiex and PPD, she strategized and managed all preclinical and clinical activities for drug development programs and was responsible for identification of new partnering opportunities and technical due diligence for both in-licensing opportunities and new business acquisitions. She led the partnering and the in-licensing of Nesina™ from Syrrx, Inc. at preclinical stage and the licensing to Takeda at Phase 2. She was instrumental to the licensing of Priligy™ to what is currently Johnson & Johnson and then The Menarini Group. She played a pivotal role in the $1.1B acquisition of Allergan in 2014 and successfully negotiated with Controlled Substances Staff on scheduling for Viberzi®. Dr. McIntyre has authored more than 30 regulatory submissions. Her experience covers multiple therapeutic areas such as oncology (including immune-oncology), infectious diseases, central nervous system, gastrointestinal, and metabolic/endocrine as well as various therapeutic modalities including small molecules, treatment vaccines, antibodies, immunoconjugates and peptide mimetics. Dr. McIntyre is a board-certified toxicologist and board certified in Clinical Pathology (hematology and clinical chemistry) by the American Society of Clinical Pathology. Dr. McIntyre received her B.A. in Biology from Merrimack College. She earned M.S. and Ph.D. degrees in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.